Dry Eye

Ophthalmology
34
Pipeline Programs
12
Companies
50
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
2
11
0
2
17
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Alcon
AlconFORT WORTH, TX
32 programs
1
1
7
Sodium HyaluronatePhase 41 trial
SystanePhase 41 trial
Systane CompletePhase 41 trial
Systane Hydration PFPhase 41 trial
Systane UltraPhase 41 trial
+27 more programs
Active Trials
NCT00522847CompletedEst. Sep 2007
NCT05239494CompletedEst. Aug 2023
NCT04105842CompletedEst. Jul 2022
+28 more trials
Bausch + Lomb
Bausch + LombNJ - Bridgewater
13 programs
1
1
5
Lifitegrast 5% Ophthalmic SolutionPhase 41 trial
MieboPhase 41 trial
MieboPhase 41 trial
MieboPhase 41 trial
Perfluorohexyloctane ophthalmic solutionPhase 41 trial
+8 more programs
Active Trials
NCT01791426Withdrawn0Est. Oct 2013
NCT02975102Completed87Est. Sep 2019
NCT03368404Completed92Est. Jun 2020
+10 more trials
S
SantenCA - Emeryville
9 programs
1
4
1
1
IKERVIS®1mg/mLPhase 41 trial
3% DE-089 ophthalmic solutionPhase 31 trial
DE-089 ophthalmic solutionPhase 21 trial
DE-110 ophthalmic suspension high dosePhase 21 trial
NOVA22007 ''Cyclosporine''Phase 21 trial
+4 more programs
Active Trials
NCT04952987UnknownEst. Dec 2021
NCT01101984Completed400Est. Apr 2012
NCT01118754Completed132Est. Dec 2010
+6 more trials
Novartis
NovartisBASEL, Switzerland
5 programs
2
3
Lifitegrast 5% Ophthalmic SolutionPhase 41 trial
Pre-LASIK 0.3% hypromellosePhase 41 trial
XiidraPhase 41 trial
ECF843Phase 21 trial
LME636 ophthalmic solutionPhase 21 trial
Active Trials
NCT04391894Completed718Est. May 2021
NCT02365519Completed514Est. Oct 2015
NCT03952481Withdrawn0Est. Dec 2021
+2 more trials
Thea Pharma
Thea PharmaMA - Waltham
4 programs
1
Hydrocortisone OphthalmicPhase 41 trial
T2769N/A1 trial
T2769N/A1 trial
Thealoz DuoN/A1 trial
Active Trials
NCT05965778CompletedEst. Aug 2024
NCT05931861CompletedEst. Dec 2023
NCT04803240CompletedEst. Mar 2020
+1 more trials
Palatin Technologies
1 program
1
Vehicle Ophthalmic SolutionPhase 31 trial
Active Trials
NCT05201170CompletedEst. Nov 2023
VP
Vanda PharmaceuticalsWASHINGTON, DC
2 programs
2
VSJ-110Phase 21 trial
VSJ-110Phase 21 trial
Active Trials
NCT06296966Recruiting40Est. Jul 2024
NCT07179055Recruiting160Est. Sep 2026
Abbott
AbbottABBOTT PARK, IL
1 program
1
Artificial Tears Study in Mild to Moderate Dry Eye PatientsPhase 21 trial
Active Trials
NCT00607776Completed110Est. Apr 2007
Genentech
GenentechCA - Oceanside
1 program
1
DNasePhase 1/21 trial
Active Trials
NCT02193490Terminated47Est. Oct 2017
T-Therapeutics
T-TherapeuticsUK - Cambridge
2 programs
Low-Level Light TherapyN/A1 trial
Low-Level Light TherapyN/A1 trial
Active Trials
NCT07067294CompletedEst. Sep 2025
NCT07181668CompletedEst. Jul 2025
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
Next Generation Emulsion Preservative Free Eye DropsN/A1 trial
Optive MEGA-3N/A1 trial
Active Trials
NCT06443775Completed47Est. Oct 2024
NCT06439394Completed52Est. Jul 2024
Lumenis
LumenisAustralia - Chatswood
1 program
Intense Pulsed LightN/A1 trial
Active Trials
NCT03265652Completed24Est. Apr 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bausch + LombPerfluorohexyloctane ophthalmic solution
Bausch + LombMiebo
Bausch + LombMiebo
Bausch + LombMiebo
Bausch + LombLifitegrast 5% Ophthalmic Solution
Thea PharmaHydrocortisone Ophthalmic
AlconSystane Hydration PF
NovartisXiidra
NovartisLifitegrast 5% Ophthalmic Solution
SantenIKERVIS®1mg/mL
AlconiLux® system
AlconSystane Complete
AlconSystane Ultra Lubricant Eye Drops
NovartisPre-LASIK 0.3% hypromellose
AlconSodium Hyaluronate

Showing 15 of 48 trials with date data

Clinical Trials (50)

Total enrollment: 5,159 patients across 50 trials

NCT07054606Bausch + LombPerfluorohexyloctane ophthalmic solution

A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear

Start: Jul 2025Est. completion: Nov 2025104 patients
Phase 4Completed
NCT06565650Bausch + LombMiebo

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

Start: Jul 2024Est. completion: Nov 2025216 patients
Phase 4Active Not Recruiting
NCT06346340Bausch + LombMiebo

A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy

Start: Apr 2024Est. completion: Feb 202597 patients
Phase 4Completed
NCT06309953Bausch + LombMiebo

A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

Start: Feb 2024Est. completion: Jun 202499 patients
Phase 4Completed
NCT05505292Bausch + LombLifitegrast 5% Ophthalmic Solution

Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers

Start: Sep 2022Est. completion: May 202332 patients
Phase 4Completed
NCT05159284Thea PharmaHydrocortisone Ophthalmic

Efficacy and Safety of Topical Hydrocortisone on Signs and Symptoms of Dry Eye Associated to Meibomian Gland Dysfunction

Start: Nov 2021Est. completion: Mar 2025
Phase 4Recruiting
NCT04837807AlconSystane Hydration PF

Digital Device Users Who Are Treated With Systane Hydration PF

Start: Aug 2021Est. completion: Nov 2021
Phase 4Completed
NCT04297618NovartisXiidra

The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens Wearers

Start: Jul 2021Est. completion: Apr 202445 patients
Phase 4Completed
NCT03952481NovartisLifitegrast 5% Ophthalmic Solution

Effect of Lifitegrast 5% on Tear Film Markers

Start: Mar 2021Est. completion: Dec 20210
Phase 4Withdrawn
NCT04492878SantenIKERVIS®1mg/mL

Efficacy and Safety of Ikervis Under Controlled Environmental Conditions Environment

Start: Feb 2020Est. completion: Jan 2021
Phase 4Completed
NCT04159935AlconiLux® system

Investigating iLux Efficacy in Contact Lens Wearers With Evaporative Dry Eye Disease

Start: Nov 2019Est. completion: Apr 2020
Phase 4Terminated
NCT03848221AlconSystane Complete

Direct Application of Systane Complete to Contact Lenses

Start: May 2019Est. completion: Oct 2019
Phase 4Completed
NCT01086774AlconSystane Ultra Lubricant Eye Drops

Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects

Start: Jul 201010 patients
Phase 4Completed
NCT00909324NovartisPre-LASIK 0.3% hypromellose

Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery

Start: Aug 2009Est. completion: Jan 2010170 patients
Phase 4Completed
NCT00809198AlconSodium Hyaluronate

Kynex Versus Refresh Plus Study in Subject With Dry Eye

Start: Dec 2008Est. completion: May 200967 patients
Phase 4Completed
NCT00781092AlconSystane Ultra

A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes

Start: Oct 2008Est. completion: Mar 2009
Phase 4Completed
NCT00724412AlconSystane

Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye

Start: Apr 2008Est. completion: Feb 2009
Phase 4Completed
NCT01240382Santen3% DE-089 ophthalmic solution

Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

332 patients
Phase 3Completed
NCT05201170Palatin TechnologiesVehicle Ophthalmic Solution

A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye

Start: Dec 2021Est. completion: Nov 2023
Phase 3Completed
NCT01189032SantenDE-089 ophthalmic solution

Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

320 patients
Phase 2Completed
NCT07179055Vanda PharmaceuticalsVSJ-110

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

Start: Oct 2025Est. completion: Sep 2026160 patients
Phase 2Recruiting
NCT06296966Vanda PharmaceuticalsVSJ-110

A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

Start: Feb 2024Est. completion: Jul 202440 patients
Phase 2Recruiting
NCT04391894NovartisECF843

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

Start: Oct 2020Est. completion: May 2021718 patients
Phase 2Completed
NCT02365519NovartisLME636 ophthalmic solution

LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease

Start: Mar 2015Est. completion: Oct 2015514 patients
Phase 2Completed
NCT01239069SantenDE-110 ophthalmic suspension high dose

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

Start: Nov 2010Est. completion: Oct 2011140 patients
Phase 2Completed
NCT00814944SantenSirolimus

A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model

Start: Apr 2009Est. completion: Oct 2009143 patients
Phase 2Completed
NCT00739349SantenNOVA22007 ''Cyclosporine''

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

Start: Aug 2008Est. completion: Jan 2009132 patients
Phase 2Completed
NCT00607776AbbottArtificial Tears Study in Mild to Moderate Dry Eye Patients

Artificial Tears Study in Mild to Moderate Dry Eye Patients

Start: Jan 2007Est. completion: Apr 2007110 patients
Phase 2Completed
NCT00560638Bausch + Lombloteprednol etabonate ophthalmic suspension, 0.5%

Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye

Start: Nov 2005Est. completion: Feb 2006119 patients
Phase 2Completed
NCT02193490GenentechDNase

DNase Treatment for Dry Eyes

Start: Jul 2014Est. completion: Oct 201747 patients
Phase 1/2Terminated
NCT01118754SantenDE-101 ophthalmic suspension

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Start: Apr 2010Est. completion: Dec 2010132 patients
Phase 1/2Completed
NCT01375582Bausch + LombB & L Soothe Lubricant Eye Drops

Objective Evaluation of Ocular Surface Lubricants in Two Environments

Start: Jun 2011Est. completion: Jun 201220 patients
Phase 1Completed
NCT00695435AlconTOBRADEX Ophthalmic Suspension

Tobramycin Tear Concentrations

Start: Jun 200821 patients
Phase 1Completed
NCT07067294T-TherapeuticsLow-Level Light Therapy

Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients Undergoing Cataract Surgery

Start: Jan 2025Est. completion: Sep 2025
N/ACompleted
NCT07181668T-TherapeuticsLow-Level Light Therapy

Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients Undergoing Femto-Lasik Surgery

Start: Aug 2024Est. completion: Jul 2025
N/ACompleted
NCT06443775AbbVieNext Generation Emulsion Preservative Free Eye Drops

An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)

Start: Jun 2024Est. completion: Oct 202447 patients
N/ACompleted
NCT06439394AbbVieOptive MEGA-3

An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)

Start: Jun 2024Est. completion: Jul 202452 patients
N/ACompleted
NCT05902364AlconSystane Ultra PF lubricant eye drops

Systane® Ultra Preservative Free Lubricant Eye Drops

Start: Oct 2023Est. completion: Aug 202469 patients
N/ACompleted
NCT05932238AlconPolyethylene glycol 400 and propylene glycol solution/drops - Preservative Free

Systane® Hydration PF and Systane® Hydration Preserved

Start: Oct 2023Est. completion: Sep 2024
N/ACompleted
NCT05965778Thea PharmaT2769

Performance and Safety of T2769 in DED

Start: Oct 2023Est. completion: Aug 2024
N/ACompleted
NCT05931861Thea PharmaT2769

Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.

Start: Aug 2023Est. completion: Dec 2023
N/ACompleted
NCT05741216AlconOTF Ocular Lubricant

Evaluation of Comfort of Ocular Lubricants in Symptomatic Contact Lens Wearers

Start: May 2023Est. completion: Oct 2023
N/ACompleted
NCT05239494AlconDT1 Sphere Contact Lenses

Dailies Total 1 Sphere Contact Lenses

Start: May 2022Est. completion: Aug 2023
N/ACompleted
NCT04838223Bausch + LombHyperosmolar Response

Neurosensory Abnormalities in SymptomAtic Ocular Surface Patients (NASA)

Start: Jul 2021Est. completion: Jul 20261,000 patients
N/ASuspended
NCT04952987SantenDiquafosol

Dry Eye Management With 3% Diquafosol Before and After Cataract Surgery

Start: Jan 2021Est. completion: Dec 2021
N/AUnknown
NCT04105842AlconDelfilcon A

Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type

Start: Sep 2019Est. completion: Jul 2022
N/ACompleted
NCT04803240Thea PharmaThealoz Duo

Survey: Evaluation of Ocular Surface Disease Symptoms and Patient Satisfaction With Thealoz® Duo After 84 Days of Daily Treatment

Start: Apr 2019Est. completion: Mar 2020
N/ACompleted
NCT03265652LumenisIntense Pulsed Light

IPL and MGX Versus MGX Alone in the Treatment of Dry Eye Disease Secondary to MGD

Start: May 2018Est. completion: Apr 201924 patients
N/ACompleted
NCT03368404Bausch + LombCBL-102 eye drops

A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi Eye Drops in the Management of Dry Eye

Start: Nov 2017Est. completion: Jun 202092 patients
N/ACompleted
NCT02975102Bausch + LombCBL-101 Eye Drops

A Study to Evaluate the Performance and Safety of CBL-101 Versus Vismed® Multi Eye Drops in the Management of Dry Eye

Start: Mar 2017Est. completion: Sep 201987 patients
N/ACompleted

Related Jobs in Ophthalmology

Delegado Especialista Ventas Oftalmología (Retina)

AbbVie
Remote
6d ago

Account Consultant, Interventional Glaucoma - Tampa, FL

AbbVie
Remote
6d ago

Associate Director US Marketing Ophthalmology Scientific Strategy

Merck & Co.
USA - Pennsylvania - North Wales (Upper Gwynedd)
6d ago
$142K - $224K/yr

Territory Business Manager – Ophthalmology (North Jersey)

Apellis Pharmaceuticals
Field, US
1w ago
$160K - $240K/yr

Medical Director, Opthalmology

AAVantgarde Bio
London
2w ago

Field Service Engineer

iVis Technologies
Remote
2w ago
$70K - $100K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 5,159 patients
12 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Open-Angle Glaucoma(102)Glaucoma(92)Age-Related Macular Degeneration(73)Dry Eye Disease(43)Neovascular Age-related Macular Degeneration(40)Macular Degeneration(37)Diabetic Retinopathy(25)Cataracts(22)